US$ 25.79
human trials bpc-157 and the Difference Between an Evidence Gap and a Cover-Up: What the entire evidence base actually looks like, and the questions to ask next. — WellFounded bpc-157 human clinical trials safety
Description
& Runmarker, B
A., Munshi, C., Lee, H

Conclusion Peptides (and in fact any substance) poses substantial public health risks, stemming from five critical safety deficiencies: inadequate human clinical data to determine efficacy and appropriate dosing

No serious TEAEs, TEAEs leading to study withdrawal or deaths were reported

Once reconstituted, solutions require immediate refrigeration between 2C to 8C to maintain molecular integrity over subsequent experimental phases